Charles Schwab’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-148,706
| Closed | -$7.11M | – | 3502 |
|
|
2025
Q3 | $7.11M | Buy |
148,706
+92,004
| +162% | +$2.55M | ﹤0.01% | 2282 |
|
|
2025
Q2 | $907K | Sell |
56,702
-9,148
| -14% | -$148K | ﹤0.01% | 2929 |
|
|
2025
Q1 | $1M | Buy |
65,850
+1,791
| +3% | +$28.7K | ﹤0.01% | 2841 |
|
|
2024
Q4 | $1.3M | Buy |
64,059
+488
| +0.8% | +$12.3K | ﹤0.01% | 2820 |
|
|
2024
Q3 | $1.63M | Buy |
63,571
+2,147
| +3% | +$35.8K | ﹤0.01% | 2761 |
|
|
2024
Q2 | $790K | Buy |
+61,424
| New | +$988K | ﹤0.01% | 3019 |
|
|
2023
Q4 | – | Sell |
-1,371
| Closed | -$38.5K | – | 3569 |
|
|
2023
Q3 | $38.5K | Hold |
1,371
| – | – | ﹤0.01% | 3429 |
|
|
2023
Q2 | $41.7K | Sell |
1,371
-3,678
| -73% | -$93.9K | ﹤0.01% | 3439 |
|
|
2023
Q1 | $94.9K | Hold |
5,049
| – | – | ﹤0.01% | 3257 |
|
|
2022
Q4 | $51.5K | Sell |
5,049
-354
| -7% | -$5.69K | ﹤0.01% | 3352 |
|
|
2022
Q3 | $143K | Hold |
5,403
| – | – | ﹤0.01% | 3198 |
|
|
2022
Q2 | $244K | Buy |
5,403
+197
| +4% | +$15.5K | ﹤0.01% | 3218 |
|
|
2022
Q1 | $513K | Buy |
5,206
+235
| +5% | +$22K | ﹤0.01% | 3096 |
|
|
2021
Q4 | $761K | Buy |
4,971
+2,730
| +122% | +$404K | ﹤0.01% | 3015 |
|
|
2021
Q3 | $304K | Hold |
2,241
| – | – | ﹤0.01% | 3265 |
|
|
2021
Q2 | $330K | Buy |
+2,241
| New | +$343K | ﹤0.01% | 3226 |
|
Charles Schwab's TRML Position: Q4 2025 in Review
Charles Schwab sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 148,706 shares — an estimated $7.11M sold.
Charles Schwab first reported a position in TRML in Q2 2021 and held it in 16 quarters. The position peaked at $7.11M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Charles Schwab reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Charles Schwab sold 148,706 Tourmaline Bio shares in Q4 2025, an estimated $7.11M.
- Charles Schwab first reported a position in Tourmaline Bio in Q2 2021 and held it in 16 quarters.
- Charles Schwab's Tourmaline Bio position peaked at $7.11M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Charles Schwab's 13F filing for Q4 2025, filed 13 Feb 2026.